- Home
- SILC vs OKUR Comparison
SILC vs OKUR Comparison
Compare SILC & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- OKUR
- Stock Information
- Founded
- SILC 1987
- OKUR 2011
- Country
- SILC Israel
- OKUR United States
- Employees
- SILC N/A
- OKUR N/A
- Industry
- SILC Computer Manufacturing
- OKUR
- Sector
- SILC Technology
- OKUR
- Exchange
- SILC Nasdaq
- OKUR NYSE
- Market Cap
- SILC 91.4M
- OKUR 76.6M
- IPO Year
- SILC 1994
- OKUR N/A
- Fundamental
- Price
- SILC $14.90
- OKUR $4.32
- Analyst Decision
- SILC Hold
- OKUR Strong Buy
- Analyst Count
- SILC 2
- OKUR 4
- Target Price
- SILC N/A
- OKUR $32.25
- AVG Volume (30 Days)
- SILC 26.2K
- OKUR 31.6K
- Earning Date
- SILC 05-01-2025
- OKUR 03-10-2025
- Dividend Yield
- SILC N/A
- OKUR N/A
- EPS Growth
- SILC N/A
- OKUR N/A
- EPS
- SILC N/A
- OKUR N/A
- Revenue
- SILC $58,114,000.00
- OKUR N/A
- Revenue This Year
- SILC $6.22
- OKUR N/A
- Revenue Next Year
- SILC $19.10
- OKUR N/A
- P/E Ratio
- SILC N/A
- OKUR N/A
- Revenue Growth
- SILC N/A
- OKUR N/A
- 52 Week Low
- SILC $11.35
- OKUR $4.29
- 52 Week High
- SILC $18.24
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- SILC 39.78
- OKUR N/A
- Support Level
- SILC $14.38
- OKUR N/A
- Resistance Level
- SILC $15.37
- OKUR N/A
- Average True Range (ATR)
- SILC 0.68
- OKUR 0.00
- MACD
- SILC 0.04
- OKUR 0.00
- Stochastic Oscillator
- SILC 17.87
- OKUR 0.00
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.